NOT FOR DISTRIBUTION
Header cover image

Market Cap

€574.0m

Last Updated

2021/05/15 18:52 UTC

Data Sources

Company Financials +

Executive Summary

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. More Details


Snowflake Analysis

High growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has DBV Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DBV is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: DBV's weekly volatility has decreased from 15% to 8% over the past year, but is still higher than 75% of French stocks.


Market Performance


7 Day Return

-2.2%

DBV

-2.6%

FR Biotechs

-0.2%

FR Market


1 Year Return

10.9%

DBV

35.2%

FR Biotechs

48.5%

FR Market

Return vs Industry: DBV underperformed the French Biotechs industry which returned 35.7% over the past year.

Return vs Market: DBV underperformed the French Market which returned 48.4% over the past year.


Shareholder returns

DBVIndustryMarket
7 Day-2.2%-2.6%-0.2%
30 Day-2.3%-5.5%2.2%
90 Day9.9%-16.9%11.0%
1 Year10.9%10.9%35.2%35.2%52.4%48.5%
3 Year-75.1%-75.1%-20.5%-20.5%26.1%15.2%
5 Year-80.6%-80.6%-48.4%-48.5%78.3%55.2%

Long-Term Price Volatility Vs. Market

How volatile is DBV Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is DBV Technologies undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: DBV (€10.46) is trading below our estimate of fair value (€51.19)

Significantly Below Fair Value: DBV is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: DBV is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: DBV is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DBV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DBV is good value based on its PB Ratio (4.1x) compared to the FR Biotechs industry average (4.3x).


Future Growth

How is DBV Technologies forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

64.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DBV is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.4%).

Earnings vs Market: DBV is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: DBV's is expected to become profitable in the next 3 years.

Revenue vs Market: DBV's revenue (69.7% per year) is forecast to grow faster than the French market (6.8% per year).

High Growth Revenue: DBV's revenue (69.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DBV's Return on Equity is forecast to be high in 3 years time


Past Performance

How has DBV Technologies performed over the past 5 years?

-9.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DBV is currently unprofitable.

Growing Profit Margin: DBV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DBV is unprofitable, and losses have increased over the past 5 years at a rate of 9% per year.

Accelerating Growth: Unable to compare DBV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DBV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (21.8%).


Return on Equity

High ROE: DBV has a negative Return on Equity (-87.54%), as it is currently unprofitable.


Financial Health

How is DBV Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: DBV's short term assets ($159.8M) exceed its short term liabilities ($38.8M).

Long Term Liabilities: DBV's short term assets ($159.8M) exceed its long term liabilities ($13.4M).


Debt to Equity History and Analysis

Debt Level: DBV's debt to equity ratio (0.6%) is considered satisfactory.

Reducing Debt: DBV's debt to equity ratio has reduced from 1.7% to 0.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DBV has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: DBV has less than a year of cash runway if free cash flow continues to reduce at historical rates of 22.8% each year


Dividend

What is DBV Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DBV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DBV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DBV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DBV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DBV's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Daniel Tassé (60 yo)

2.5yrs

Tenure

US$2,062,135

Compensation

Mr. Daniel Tasse had been an Independent Non-Executive Director of Indivior PLC since August 2014 until May 6, 2021 and had been its Senior Independent Director since September 30, 2016 until May 6, 2021. ...


CEO Compensation Analysis

Compensation vs Market: Daniel's total compensation ($USD2.06M) is above average for companies of similar size in the French market ($USD559.50K).

Compensation vs Earnings: Daniel's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: DBV's management team is considered experienced (2.2 years average tenure).


Board Members

Experienced Board: DBV's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

DBV Technologies S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: DBV Technologies S.A.
  • Ticker: DBV
  • Exchange: ENXTPA
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €574.004m
  • Shares outstanding: 54.88m
  • Website: https://www.dbv-technologies.com

Number of Employees


Location

  • DBV Technologies S.A.
  • 177-181 Avenue Pierre Brossolette
  • Montrouge
  • Ile-de-France
  • 92120
  • France

Listings


Biography

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunothe...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/15 18:52
End of Day Share Price2021/05/14 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.